Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Chemotherapy and Pharmacology
Published in: Cancer Chemotherapy and Pharmacology 1/2001

01-06-2001 | ORIGINAL ARTICLE

Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16

Authors: Martin Wald, Tomáš Olejár, Veronika Šebková, Marie Zadinová, Michal Boubelík, Pavla Poučková

Published in: Cancer Chemotherapy and Pharmacology | Special Issue 1/2001

Login to get access
Metadata
Title
Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16
Authors
Martin Wald
Tomáš Olejár
Veronika Šebková
Marie Zadinová
Michal Boubelík
Pavla Poučková
Publication date
01-06-2001
Publisher
Springer-Verlag
Published in
Cancer Chemotherapy and Pharmacology / Issue Special Issue 1/2001
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s002800170004

Other articles of this Special Issue 1/2001

Cancer Chemotherapy and Pharmacology 1/2001 Go to the issue

ORIGINAL ARTICLE

Co-medication with hydrolytic enzymes in radiation therapy of uterine cervix: evidence of the reduction of acute side effects

ORIGINAL ARTICLE

Oral therapy with proteolytic enzymes decreases excessive TGF-β levels in human blood

ORIGINAL ARTICLE

Efficacy of hydrolytic enzymes in preventing radiation therapy-induced side effects in patients with head and neck cancers

ORIGINAL ARTICLE

Impact of complementary oral enzyme application on the postoperative treatment results of breast cancer patients – results of an epidemiological multicentre retrolective cohort study

ORIGINAL ARTICLE

Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma

ORIGINAL ARTICLE

Modulation of growth factor binding properties of a2-macroglobulin by enzyme therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits